Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6–10 months old water buffalo (Bubalus bubalis)

Diptee, Michael; Adesiyun, Abiodun A.; Asgarali, Zinora; Campbell, Michael H.; Adone, Rosanna

doi:10.1016/j.vetimm.2005.07.020

Cited by 14 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A poor reactivity of anti‐bovine conjugate to the buffalo sera might be another possible explanation but high reactivity (up to 82.63% positivity in 3ANSP‐ELISA; data not presented) shown by some of the sera does not support this hypothesis. In addition, there are reports where anti‐bovine conjugate has been used to detect buffalo sera (Diptee et al., 2006). Third and the most possible explanation might be the cut‐off limit of the test; the cut‐off value (20%) was determined by utilizing the cattle sera collected from different parts of Germany.…”

Section: Discussionmentioning

confidence: 99%

Non‐Structural Protein 3A for Differentiation of Foot‐and‐Mouth Disease Infected and Vaccinated Animals in Haryana (India)

Kumar

Sharma

Kakker

2007

Zoonoses and Public Health

View full text Add to dashboard Cite

There are severe international trade restrictions on foot-and-mouth disease (FMD) affected areas. Because of endemic nature of FMD, India started FMD control programme (FMD-CP) using mass vaccination in selected states including Haryana (year 2003). Although no significant incidence of the disease was reported after launching FMD-CP in the state but in order to participate in international trade of animal and animal products, veterinary authorities have to prove that there is no FMD virus (FMDV) circulation in the animal population, for which it is necessary to differentiate the FMD infected and vaccinated animals. For this purpose, an in-house indirect ELISA utilizing baculovirus-expressed FMDV non-structural protein (NSP) 3A was used to find evidence for virus circulation (prevalence of anti-NSP 3A-specific antibodies) by examining serum samples that were collected either before start of FMD-CP or after completion of third phase (Pre-4th) of vaccination in Haryana (India). A significant reduction (P < 0.01) in prevalence of anti-NSP 3A-specific antibodies (possibly carriers) was observed 2 years after launching FMD-CP in Haryana. However, in cattle the percentage of animals with anti-NSP 3A-specific antibodies was found to be significantly higher (P < 0.01) than buffalo, both before (P < 0.01) and after (P < 0.01) launching FMD-CP in the state. The findings of this study suggest that use of FMDV vaccine in cattle and buffaloes in endemic areas reduces virus circulation (carriers) in the vaccinated herds and that the current 3ANSP-ELISA can be successfully used to monitor the FMDV circulation in endemic areas.

show abstract

Section: Discussionmentioning

confidence: 99%

Non‐Structural Protein 3A for Differentiation of Foot‐and‐Mouth Disease Infected and Vaccinated Animals in Haryana (India)

Kumar

Sharma

Kakker

2007

Zoonoses and Public Health

View full text Add to dashboard Cite

show abstract

“…RB51 was cleared from vaccinated water buffalo calves between 6 and 12 weeks post-vaccination at the recommended dose (Diptee et al 2005), similar to clearance in bovine calves. Lateral transmission of RB51 and environmental shedding of RB51 antigen from mucosal surfaces did not occur (Diptee et al 2006). Eight percent (two of 24) of vaccinated water buffalo were persistently infected with RB51 through the first year after inoculation.…”

Section: Ruminant Studiesmentioning

confidence: 93%

“…Evaluation of RB51 vaccine in domestic water buffalo B. abortus RB51 vaccine does not induce in water buffalo serum antibodies that react in the BPAT and c-ELISA (Diptee et al 2006(Diptee et al , 2007Fosgate et al 2003b). Both complement fixation (CF) and dot-blot ELISA can be used to monitor antibody response to RB51 vaccination in water buffalo, but CF has higher sensitivity.…”

Section: Ruminant Studiesmentioning

confidence: 99%

Brucellosis in domestic water buffalo (Bubalus bubalis) of Trinidad and Tobago with comparative epidemiology to cattle

Fosgate

Diptee

Ramnanan³

et al. 2011

Trop Anim Health Prod

View full text Add to dashboard Cite

The water buffalo is an important domestic animal worldwide, and the local Buffalypso variety was developed in Trinidad to have improved beef qualities. Brucellosis was diagnosed in Trinidad and Tobago during 1998 in both cattle and domestic water buffalo (Bubalus bubalis) populations. Brucellosis in the latter species is caused by infection with Brucella abortus, similar to bovine brucellosis. Control of brucellosis is of paramount importance to preservation of the genetic diversity of these animals in Trinidad, and this has been complicated by differences in the epidemiology of water buffalo and bovine brucellosis. Some diagnostic tests do not have comparable accuracy between the two species, and the RB51 vaccine does not adequately protect against infection in water buffalo. The water buffalo in Trinidad may also be more resistant to infection than cattle. Development of effective vaccination protocols is key to brucellosis control in Buffalypso in Trinidad, and prohibitions on import of virulent B. abortus strains for vaccine efficacy studies has impeded progress in this area. These Trinidadian strains are of variable virulence; some might be effective for challenge in vaccine efficacy studies, while other, of lower virulence, may be vaccine candidates for use in water buffalo.

show abstract

“…RB51 can be safely used in water buffalo (Diptee et al, 2006), but it is not protective against natural Brucella infections, as evidenced by the percentage of vaccinated animals seroconverting was greater than the control group (43% versus 15%), and all isolates were confirmed to be B. abortus biovar 1 and not RB51 (Fosgate et al, 2003). RB51 is safe in small ruminants (Roop et al, 1991), but it does not protect sheep against abortion induced by wt B. melitensis (el Idrissi et al, 2001), nor does RB51 confer protection against B. ovis in goats (Jiménez de Bagüés et al, 1995; Herrera et al, 2011).…”

Section: Live Vaccinesmentioning

confidence: 99%

Progress in Brucella vaccine development

et al. 2012

View full text Add to dashboard Cite

Brucella spp. are zoonotic, facultative intracellular pathogens, which cause animal and human disease. Animal disease results in abortion of fetuses; in humans, it manifests flu-like symptoms with an undulant fever, with osteoarthritis as a common complication of infection. Antibiotic regimens for human brucellosis patients may last several months and are not always completely effective. While there are no vaccines for humans, several licensed live Brucella vaccines are available for use in livestock. The performance of these animal vaccines is dependent upon the host species, dose, and route of immunization. Newly engineered live vaccines, lacking well-defined virulence factors, retain low residual virulence, are highly protective, and may someday replace currently used animal vaccines. These also have possible human applications. Moreover, due to their enhanced safety and efficacy in animal models, subunit vaccines for brucellosis show great promise for their application in livestock and humans. This review summarizes the progress of brucellosis vaccine development and presents an overview of candidate vaccines.

show abstract

Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6–10 months old water buffalo (Bubalus bubalis)

Cited by 14 publications

References 24 publications

Non‐Structural Protein 3A for Differentiation of Foot‐and‐Mouth Disease Infected and Vaccinated Animals in Haryana (India)

Non‐Structural Protein 3A for Differentiation of Foot‐and‐Mouth Disease Infected and Vaccinated Animals in Haryana (India)

Brucellosis in domestic water buffalo (Bubalus bubalis) of Trinidad and Tobago with comparative epidemiology to cattle

Progress in Brucella vaccine development

Contact Info

Product

Resources

About